# Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy

> **NCT05136456** · PHASE2 · UNKNOWN · sponsor: **Reistone Biopharma Company Limited** · enrollment: 61 (actual)

## Conditions studied

- Primary Membranous Nephropathy

## Interventions

- **DRUG:** SHR1459 Low Dose
- **DRUG:** SHR1459 High Dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05136456
- **Lead sponsor:** Reistone Biopharma Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-15
- **Primary completion:** 2023-08-28
- **Final completion:** 2024-03-11
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05136456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05136456, "Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05136456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*